Literature DB >> 3136958

Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

O Josimovic-Alasevic1, H Feldmeier, K Zwingenberger, G Harms, H Hahn, M Shrisuphanunt, T Diamantstein.   

Abstract

An enzyme-linked immunosorbent assay was used to quantify soluble interleukin 2 receptor (IL-2R) in the serum of patients with helminthic and protozoal infections. The results demonstrated that levels of IL-2R were normal in patients with helminthic infections limited to the intestinal tract (ascariasis, trichuriasis), but significantly elevated in patients with systemic or long-lasting infections (strongyloidiasis, schistosomiasis, fascioliasis, opisthorchiasis). In patients infected with Schistosoma mansoni levels of IL-2R were higher in those with the hepatosplenic than in those with the intestinal form of the disease. Patients with malaria also showed increased serum levels of IL-2R, irrespective whether the infection was caused by Plasmodium falciparum or P. vivax. No difference was observed between patients with acute or history of malaria. The highest levels of IL-2R were observed in patients with visceral leishmaniasis. Interestingly, in these patients the concentration of IL-2R correlated to specific antibody titre. The results are discussed in the context of preferential activation of T lymphocytes, B lymphocytes and/or macrophages during the course of the different parasitic infections investigated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136958      PMCID: PMC1541536     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Enzyme-linked immunosorbent assay of mouse interleukin-2 receptors.

Authors:  H Osawa; O Josimovic-Alasevic; T Diamantstein
Journal:  J Immunol Methods       Date:  1986-08-21       Impact factor: 2.303

2.  Regulation of interleukin-2 receptor expression and receptor release.

Authors:  T Diamantstein; H Osawa; A Mouzaki; O Josimovic-Alasevic
Journal:  Mol Immunol       Date:  1986-11       Impact factor: 4.407

3.  Soluble interleukin 2 receptors are released by long term-cultured insulin-specific T cells transiently after contact with antigen.

Authors:  A B Reske-Kunz; H Osawa; O Josimović-Alasević; E Rüde; T Diamantstein
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

4.  An ELISA that detects cell-associated and released rat IL-2 receptors in a soluble form.

Authors:  A Mouzaki; H Osawa; T Diamantstein
Journal:  J Immunol Methods       Date:  1987-06-26       Impact factor: 2.303

5.  Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease.

Authors:  D G Colley; A A Garcia; J R Lambertucci; J C Parra; N Katz; R S Rocha; G Gazzinelli
Journal:  Am J Trop Med Hyg       Date:  1986-07       Impact factor: 2.345

6.  Suppression of the local graft-vs.-host reaction in rats by treatment with a monoclonal antibody specific for the interleukin 2 receptor.

Authors:  H D Volk; S Brocke; H Osawa; T Diamantstein
Journal:  Eur J Immunol       Date:  1986-10       Impact factor: 5.532

7.  B lymphocyte population and immunoglobulins in Indian kala-azar in response to chemotherapy.

Authors:  A B Neogy; A Nandy; B G Dastidar; A B Chowdhury
Journal:  Acta Trop       Date:  1986-09       Impact factor: 3.112

8.  Plasma interleukin 2 receptor levels in renal allograft recipients.

Authors:  R B Colvin; T C Fuller; L MacKeen; P C Kung; S H Ip; A B Cosimi
Journal:  Clin Immunol Immunopathol       Date:  1987-05

9.  Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

Authors:  G Pizzolo; M Chilosi; F Vinante; F Dazzi; M Lestani; G Perona; F Benedetti; G Todeschini; C Vincenzi; L Trentin
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

10.  Determination of cell-free interleukin 2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity.

Authors:  V Schirrmacher; O Josimovic-Alasevic; H Osawa; T Diamantstein
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

View more
  19 in total

1.  Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Authors:  J E Crabtree; L D Juby; R V Heatley; A J Lobo; D W Bullimore; A T Axon
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

2.  Serum sIL-2R, TNF-alpha and IFN-gamma in alveolar echinococcosis.

Authors:  Da-Zhong Shi; Fu-Rong Li; B Bartholomot; D A Vuitton; P S Craig
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

3.  Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.

Authors:  R Harpaz; R Edelman; S S Wasserman; M M Levine; J R Davis; M B Sztein
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria.

Authors:  L Hviid; J A Kurtzhals; B Q Goka; J O Oliver-Commey; F K Nkrumah; T G Theander
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria.

Authors:  B F Chumpitazi; F Peyron; J Simon; C Boudin; I Sheick-Zakiuddin; S Picot; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

6.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

7.  Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria.

Authors:  P Deloron; J P Lepers; P Coulanges
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

8.  Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Authors:  R Meliconi; E Lalli; R M Borzì; C Sturani; V Galavotti; G Gunella; R Miniero; A Facchini; G Gasbarrini
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

9.  Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.

Authors:  Shigenori Kanazawa; Kazuyuki Yamaguchi; Yoshimi Kinoshita; Yutaka Komiyama; Mikiko Muramatsu; Shosaku Nomura
Journal:  J Cancer Res Clin Oncol       Date:  2006-07-12       Impact factor: 4.553

10.  Immunological markers of childhood fevers in an area of intense and perennial malaria transmission.

Authors:  N Hurt; M Thein; T Smith; G Bordmann; H Gallati; N Drees; M Tanner; N Weiss
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.